Han Xuan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Han Xuan has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Changhua Yu
Shenzhen People’s Hospital, China
1 shared publication - Cong Liang Zhang
He Third People's Hospital of Longgang District, Shenzhen,China, China
1 shared publication - Guoqing Dong
Shenzhen Maternity and Child Healthcare Hospital, Women and Children’s Medical Center, Southern Medical University
1 shared publication - Qianqian Chen
Otolaryngology, Longgang Otolaryngology Hospital,Shenzhen,Guangdong,China, China
1 shared publication - Qiaorong Chen
Shenzhen People’s Hospital, China
1 shared publication - Qin Zhang
深圳市儿童医院, China
1 shared publication
Latest Publications
- Open Access
- 27 February 2026
- Published by MDPI AG in Preprints.org
Experiences of Clinical Practice-Based Treatment with a 3-Month Dosage Form of Leuprorelin
Objectives: Despite the widespread use of the leuprorelin 3-month depot in central precocious puberty (CPP), its clinical efficacy and patient follow-up remain unexplored. This study aimed to compare the clinical indicators of the leuprorelin 3-month depot and triptorelin 1-month depot following treatment in a CPP cohort to understand the therapeutic effect of the former.Methods: A retrospective analysis was performed on 60 children diagnosed with progressive idiopathic CPP or precocious puberty who received at least 24 months of treatment at the hospital. The treatment involved leuprorelin 3-month depot for 18 participants, triptorelin 1-month depot for 16 participants, and a combination of both drugs for 26 participants. Anthropometric, biochemical, and bone age (BA) data were examined before treatment and every 12 months during treatment.Results: Before treatment, no statistical differences were noted in the baseline levels of sex hormones (oestradiol (E2), luteinising hormone (LH), and follicle-stimulating hormone (FSH)) among the triptorelin 1-month depot, leuprorelin 3-month depot, and combination therapy groups (P>0.05). However, the serum testosterone levels among participants were statistically significant (P < 0.05). After 1 and 2 years of treatment, no statistically significant differences were noted in the baseline levels of sex hormones (E2, LH, and FSH) among the three groups (P>0.05). At baseline, no statistical differences were found in BA, height, or weight among the groups (P>0.05). After 1 and 2 years of treatment, no statistically significant differences were observed in the growth rate, maturity, or BA growth rate of the participants in all three groups (P>0.05).Conclusions: The therapeutic effects of the triptorelin 1-month and leuprorelin 3-month depots were equivalent. Furthermore, treatment with leuprorelin 3-month depot is cost-effective compared with the other options . It reduces the number of injections administered to paediatric patients, the time spent on medical visits, and improves compliance, leading to greater acceptance among patients.
- 27 February 2026
- Published by MDPI AG in Preprints.org
Open AccessExperiences of Clinical Practice-Based Treatment with a 3-Month Dosage Form of Leuprorelin
Objectives: Despite the widespread use of the leuprorelin 3-month depot in central precocious puberty (CPP), its clinical efficacy and patient follow-up remain unexplored. This study aimed to compare the clinical indicators of the leuprorelin 3-month depot and triptorelin 1-month depot following treatment in a CPP cohort to understand the therapeutic effect of the former.Methods: A retrospective analysis was performed on 60 children diagnosed with progressive idiopathic CPP or precocious puberty who received at least 24 months of treatment at the hospital. The treatment involved leuprorelin 3-month depot for 18 participants, triptorelin 1-month depot for 16 participants, and a combination of both drugs for 26 participants. Anthropometric, biochemical, and bone age (BA) data were examined before treatment and every 12 months during treatment.Results: Before treatment, no statistical differences were noted in the baseline levels of sex hormones (oestradiol (E2), luteinising hormone (LH), and follicle-stimulating hormone (FSH)) among the triptorelin 1-month depot, leuprorelin 3-month depot, and combination therapy groups (P>0.05). However, the serum testosterone levels among participants were statistically significant (P < 0.05). After 1 and 2 years of treatment, no statistically significant differences were noted in the baseline levels of sex hormones (E2, LH, and FSH) among the three groups (P>0.05). At baseline, no statistical differences were found in BA, height, or weight among the groups (P>0.05). After 1 and 2 years of treatment, no statistically significant differences were observed in the growth rate, maturity, or BA growth rate of the participants in all three groups (P>0.05).Conclusions: The therapeutic effects of the triptorelin 1-month and leuprorelin 3-month depots were equivalent. Furthermore, treatment with leuprorelin 3-month depot is cost-effective compared with the other options . It reduces the number of injections administered to paediatric patients, the time spent on medical visits, and improves compliance, leading to greater acceptance among patients.